Chymopapain for the treatment of intervertebral disc herniation. A preliminary report of a double-blind study.
Sixty patients with unilateral sciatica resulting from lumbar intervertebral disc herniation were entered into a double-blind study. All patients had failed to respond to conservative management, and the diagnosis had been confirmed by metrizamide myelography. Following a randomized schedule, 30 patients had intradiscal injections of chymopapain and 30 patients had intradiscal injections of an equivalent volume of normal saline solution. Complete relief of sciatica was obtained in 63% of patients treated with chymopapain, compared with 27% of saline-injected patients. Six weeks after the injection, 73% of patients treated with chymopapain and 37% of patients treated with saline solution considered that the treatment was successful. The success rate at six months was 80% for patients treated with chymopapain and 57% for saline-injected patients. From the preliminary results of this study, chymopapain is recommended for the treatment of sciatica from intervertebral disc herniation when conservative measures have failed and before disc fragment excision is considered.
D000328:Adult; D000368:Aged; D001416:Back Pain / Q000188:drug therapy / Q000209:etiology; D002917:Chymopapain / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D010450:Endopeptidases / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007405:Intervertebral Disc Displacement / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012585:Sciatica / Q000188:drug therapy* / Q000209:etiology; D012965:Sodium Chloride / Q000008:administration & dosage / Q000627:therapeutic use
D012965:Sodium Chloride; D010450:Endopeptidases; D002917:Chymopapain